Related Experiment Video
Updated: Jul 5, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
[D3 agonism: an augmentative treatment in tardive dyskinesia? A case report]
Gerald Rehor1, Meinhard Eiler, Andreas Conca
1LKH Rankweil Abteilung für Psychiatrie I, Rankweil/Osterreich. gerald@rehor.at
Objective:
Tardive dyskinesia (TD) is still a severe side effect induced by old neuroleptic drugs as well as modern atypical ones. The treatment is inefficient and often experimental. Aim of this study was to examine the effect of pramipexole, a dopamine D3 receptor agonist, in a severe case of oro-facial TD.
Method:
The TD of a 21 year old male patient with severe oro-facial occurrence was assessed by the Simpson et al scale before starting pramipexole therapy. Reevaluation was made during therapy and when the maximum dose of 1.44 mg a day was reached. Standard therapy with clozapine, valproic acid, oxazepam, bornaprin hydrochlorid and tiapride was continued as before.
Results:
Oral dyskinesia decreased 20 % and no side effects were observed. Regarding psychopathology the patient was more interested in work and showed better concentration in therapies.
Conclusion:
Pramipexole could be a new promising add-on therapy in severe TD. Additionally, the low plasma binding and mild side effect profile of pramipexole makes it safe in combination with antipsychotic therapy.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy
Antianxiety Medications
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Alzheimer's Disease: Treatment
Alterations in Muscle Tone lll
